Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more
Sandoz Group AG (SDZXF) - Total Liabilities
Latest total liabilities as of December 2025: $12.65 Billion USD
Based on the latest financial reports, Sandoz Group AG (SDZXF) has total liabilities worth $12.65 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sandoz Group AG - Total Liabilities Trend (2022–2025)
This chart illustrates how Sandoz Group AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sandoz Group AG Competitors by Total Liabilities
The table below lists competitors of Sandoz Group AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ajinomoto Co., Inc.
F:AJI0
|
Germany | €907.86 Billion |
|
Lululemon Athletica Inc.
NASDAQ:LULU
|
USA | $3.45 Billion |
|
HP Inc
NYSE:HPQ
|
USA | $42.12 Billion |
|
Las Vegas Sands Corp
NYSE:LVS
|
USA | $19.99 Billion |
|
West Pharmaceutical Services Inc
NYSE:WST
|
USA | $1.09 Billion |
|
Tyson Foods Inc
NYSE:TSN
|
USA | $18.43 Billion |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
Denmark | Dkr5.56 Billion |
|
Centene Corp
NYSE:CNC
|
USA | $56.69 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Sandoz Group AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sandoz Group AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sandoz Group AG (2022–2025)
The table below shows the annual total liabilities of Sandoz Group AG from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.65 Billion | +7.70% |
| 2024-12-31 | $11.74 Billion | +8.97% |
| 2023-12-31 | $10.78 Billion | +47136945.62% |
| 2022-12-31 | $22.86K | -- |